Cardiometabolic drugs and kidney function - a drug target Mendelian randomisation study
Aristomo Andries, Schyler Marie Bennett, Venexia M. Walker, Iris M. Heid, Anna Köttgen, Mathias Gorski, Artemis A. Briasouli, Jie Zheng, Kristian Hveem, Stein Ivar Hallan, Bjørn Olav Åsvold, Tom R. Gaunt, Ben Michael Brumpton, Humaira Rasheed
This study uses Mendelian randomization to assess how cardiometabolic drugs affect kidney function, finding specific drug targets influence eGFR and related biomarkers.
medRxiv · Jun 16, 2025 · PreprintGenetic & Genomic Medicine